Vertex PharmaceuticalsActive
Oral CFTR potentiator for cystic fibrosis. Vertex's U.S. prescriber page says Kalydeco is indicated for patients 1 month and older who have at least one CFTR mutation responsive to ivacaftor potentiation based on clinical and/or in vitro data. It remains a commercial medicine. The Q3 2026 earnings table groups it with Orkambi and Symdeko/Symkevi in other CF product revenue of $130.5 million.
Latest update Nov 5, 2026
01
Still listed on Vertex's U.S. approved-medicines page. Q3 2026 sales are inside other CF revenue of $130.5 million and are not reported alone.
02
03
The European Medicines Agency said on September 18 that Vertex Pharmaceuticals (Ireland) Limited had withdrawn applications to extend Kaftrio (ivacaftor/tezacaftor/elexacaftor) and Kalydeco (ivacaftor) to children aged one year and older with cystic fibrosis, used together as a combination regimen. The notice came in the CHMP highlights from the committee's September 14-17 meeting, which listed the pair among three already-authorised medicines whose indication-extension filings were pulled. Existing EU approvals for older patients are not themselves revoked by the withdrawals.
A Delaware federal court ruled on August 24 that Lupin's proposed generic version of Vertex's cystic fibrosis drug Kalydeco does not infringe Vertex's patents, finding Lupin's 74% ivacaftor formulation falls outside the patents' claimed 80% concentration range. The ruling clears a path for Lupin, which already holds tentative FDA approval, to launch the first generic challenger to a Vertex CF modulator pending final FDA approval.
04
Vertex's flagship cystic fibrosis triple-combination CFTR modulator (elexacaftor/tezacaftor/ivacaftor), effective for roughly 90% of CF patients and the company's dominant revenue engine - now complemented by the once-daily next-generation Alyftrek.
A first-in-class oral, non-opioid pain medicine (VX-548) that selectively inhibits the NaV1.8 sodium channel to block pain signals in the peripheral nervous system before they reach the brain - the first new class of pain drug in over 20 years.
The first approved CRISPR/Cas9 gene-editing medicine (exagamglogene autotemcel), a one-time therapy for sickle cell disease and transfusion-dependent beta thalassemia, developed and commercialized with CRISPR Therapeutics.
An allogeneic, stem-cell-derived, fully differentiated islet cell therapy for type 1 diabetes designed to restore the body's own insulin production - a potential functional cure delivered as a one-time infusion.
An oral, once-daily somatostatin receptor agonist for acromegaly, acquired through the Crinetics Pharmaceuticals deal - Vertex's first marketed product outside CF, pain, and gene therapy, and the anchor of its new endocrine-disease business.
An oral pipeline candidate for endocrine disease acquired with Crinetics Pharmaceuticals, part of the endocrinology pipeline Vertex and Crinetics said could reach $5B+ in combined peak annual sales alongside Palsonify.
Once-daily next-generation CFTR modulator (vanzacaftor/tezacaftor/deutivacaftor). The Oct. 9, 2026 company release says the US indication is patients 6 years and older with a responsive CFTR variant. Use in children ages 2 to 5 is investigational.
Dual BAFF and APRIL inhibitor being studied for IgA nephropathy. Not approved. Vertex said that if the FDA approves it, the planned launch form is a low-volume subcutaneous autoinjector given at home every 4 weeks.
Oral CFTR corrector and potentiator for cystic fibrosis. Vertex's U.S. prescriber page says Orkambi is indicated for patients 1 year and older who are homozygous for the F508del mutation, and that efficacy and safety have not been established for other genotypes. It remains a commercial medicine. The Q3 2026 earnings table groups it with Kalydeco and Symdeko/Symkevi.
Oral CFTR corrector and potentiator for cystic fibrosis. Vertex's U.S. prescriber page says Symdeko is indicated for patients 6 years and older who are homozygous for F508del or who have at least one mutation responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence. It remains a commercial medicine. Q3 2026 other CF revenue of $130.5 million includes Symdeko/Symkevi with Kalydeco and Orkambi.
05
Oklo
Oklo's fast-fission powerhouse product line is designed for build-own-operate deployment, targeting customers that want firm clean power in a smaller footprint than traditional large reactors.
Oklo
Oklo is developing an advanced fuel center to recycle used nuclear fuel and fabricate metal fuel for Aurora and other fast-reactor applications.
Oklo
Oklo's isotope business combines the Idaho Radiochemistry Laboratory, a planned pilot reactor in Texas, and a future multi-reactor foundry to supply critical medical, industrial, research, defense, and space isotopes.
TerraPower
Sodium-cooled fast reactor with integrated molten salt energy storage, enabling flexible output from 345 MWe to 500 MWe peak.